Letter from the Editor in Chief

DOI: 10.19102/icrm.2024.150110

MOUSSA MANSOUR, MD, FHRS, FACC

Download PDF

Follow Us >> Tweet

Dr. Mansour reports the reception of research grants from Abbott Laboratories, Biosense Webster, Johnson & Johnson, Boston Scientific, Medtronic, Pfizer, Boehringer Ingelheim, and SentreHeart. He is also a consultant for Abbott Laboratories, Biosense Webster, Johnson & Johnson, Boston Scientific, Janssen, Medtronic, Phillips, Novartis, and SentreHeart and reports an equity relationship with EPS Solutions. All aforementioned relationships are in the area of atrial fibrillation; Dr. Mansour additionally reports an equity relationship in the area of ventricular fibrillation with NewPace Ltd.

Dear readers,

The American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Clinical Pharmacy/Heart Rhythm Society (HRS) guidelines for the diagnosis and management of atrial fibrillation (AF) were recently published,¹ and the document has since been elegantly summarized by Wiggins et al.² These recent guidelines contain significant updates compared to the prior version of the AHA/ACC/HRS guidelines³ and the focused update⁴ published in 2014 and 2019, respectively. Among the updates, I will review two that I believe will have the most impact on the clinical practice of interventional cardiac electrophysiology.

First is the increased emphasis on rhythm control. In addition to recommending rhythm control for symptomatic patients (Class of Recommendation IIa), the guideline provides recommendations for rhythm control in some patients regardless of the presence of symptoms. These patients include those with reduced ejection fraction (Class I) and those diagnosed with AF within 1 year of presentation (Class IIa). Rhythm control is also recommended to prevent the progression of AF from paroxysmal to persistent (Class IIb) and to reduce the likelihood of dementia onset (Class IIb). More specifically, rhythm control to reduce symptoms using catheter ablation as a first-line therapy received a Class I recommendation for young patients with paroxysmal AF and few comorbidities, and a Class IIa recommendation for a less-restrictive patient population, including those with paroxysmal and persistent AF, with more comorbidities.

The second update of note is the upgraded recommendation for percutaneous left atrial appendage (LAA) occlusion (LAAO), which received a Class IIa recommendation for patients with AF, a moderate to high risk of stroke (CHA₂DS₂-VASc score ≥ 2 points), and a contraindication to long-term oral anticoagulation (OAC). Contraindication to OAC was well defined in the document and included severe bleeding due to a non-reversible cause, spontaneous intracranial/intraspinal bleeding due to a non-reversible cause, and serious bleeding related to recurrent falls when the cause of falls was not felt to be treatable. This differs from the 2019 version, where LAAO had a Class IIb recommendation for the same clinical scenario. Moreover, in the current 2023 version, LAAO as an alternative to OAC received a Class IIb recommendation for patients who are at high risk for bleeding, based on patient preference, with careful consideration of procedural risk and with the understanding that the evidence for oral anticoagulation is more extensive.

In summary, the latest guidelines provided upgraded recommendations for two cardiac EP procedures: catheter ablation and LAA closure. This was the result of landmark well-designed clinical studies that demonstrated the efficacy and safety of these two procedures, and these changes are expected to enhance clinical practice going forward.

I hope that you enjoy reading this issue of The Journal of Innovations in Cardiac Rhythm Management.

Sincerely,

Moussa Mansour, MD, FHRS, FACC

Editor in Chief

The Journal of Innovations in Cardiac Rhythm Management

MMansour@InnovationsInCRM.com

Director, Atrial Fibrillation Program

Jeremy Ruskin and Dan Starks Endowed Chair in Cardiology

Massachusetts General Hospital

Boston, MA 02114

References

1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1–e156. [CrossRef] [PubMed]
2. Wiggins BS, ACC Solution Set Oversight Committee, Cibotti-Sun M, Moore MM. 2023 atrial fibrillation guideline-at-a-glance. J Am Coll Cardiol. 2024;83(1):280–284. [CrossRef] [PubMed]
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76. [CrossRef] [PubMed]
4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. [CrossRef] [PubMed]